Semaglutide + Cagrilintide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 27 May 2022: Trial registered, NCT05394519
  2. 1 Feb 2023: Trial started, NCT05394519

The trials

NCT05394519: A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

State
Completed
Phase
Phase 3
People
1,200 taking part
Started
1 Feb 2023
Primary completion
28 Jan 2025
Arms
CagriSema
Results
None posted
  1. 27 May 2022: Trial registered
  2. 1 Feb 2023: Trial started
  3. 3 Feb 2025: Trial completed

NCT06131372: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

State
Completed
Phase
Phase 2
People
626 taking part
Started
1 Apr 2024
Primary completion
24 Sep 2025
Arms
CagriSema
Results
None posted
  1. 14 Nov 2023: Trial registered
  2. 1 Apr 2024: Trial started
  3. 6 Nov 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.